SCP-9016
Keter
?
low confidence
SCP-9016
Expected annual
$22.8M
One-time setup
$7.2M
Annual recurring
$22.6M
Personnel
16
Initial capital outlay of approximately $7.19M driven by containment retrofit (quarantine rooms), specialized imaging equipment (Astral Tomography), cGMP setup and IT/security; recurring annual operations are large (~$22.62M/yr) driven primarily by remote site overhead, ongoing research and clinical trials, staffing, and contingency/reserve funds.
One-Time Capital Costs
Total: $7.2M
Annual Recurring Costs
Total: $22.6M/yr
Cost Scenarios
📊
Baseline
(baseline)
$22.6M/yr
Normal uneventful year with routine operations, research progress at planned pace, and no major incidents.
no breach
steady research pace
routine patient care
🚨
Minor Incident
$23.1M/yr
Localized breach/flare-up or isolated structural/equipment failure requiring emergency response, targeted remediation and limited legal/amnestic actions.
localized flare-up
small containment breach
short-term MTF deployment
🚨
Major Breach
$27.6M/yr
Significant containment failure with facility damage, mass remediation/amnestics, major legal exposure and accelerated research/clinical scaling.
major containment breach
large-scale memetic leak
accelerated clinical scaling and settlements
Personnel
16 total
| Role | Count | Notes |
|---|---|---|
| Senior Doctor / Medical Officer | 2 | [#4] Senior psychiatrists/physicians included in medical staffing mix (costs accounted in staff_wages). |
| Research Scientist | 4 | [#4, #15] Memetics/psionics researchers; counts reflect staff included in staff_wages and research program support. |
| Nurse / Medical Staff | 6 | [#4] Clinical nursing staff for continuous care; included in staff_wages estimate. |
| Technician / Lab / Admin | 4 | [#4] Lab technicians, operators and administrative staff included in the staff_wages mix. |
Confidence Notes
Estimates are derived from analyst ranges but the anomalous, cognitohazardous nature of SCP-9016 and large uncertainty around research duration, breach frequency and scale of clinical development make long-term cost predictions uncertain.